Fortitude Family Office’s Amneal Pharmaceuticals AMRX Stock Holding History

Fortitude Family Office’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8K	Buy	800 +34	+4%	+$466	﹤0.01%	656
2026 Q1	$9.52K	Sell	766 -40	-5%	-$537	﹤0.01%	676
2025 Q4	$10.2K	Buy	806 +23	+3%	+$263	﹤0.01%	576
2025 Q3	$7.84K	Sell	783 -11	-1%	-$99	﹤0.01%	645
2025 Q2	$6.42K	Sell	794 -172	-18%	-$1.3K	﹤0.01%	696
2025 Q1	$8.1K	Hold	966	–	–	﹤0.01%	600
2024 Q4	$7.65K	Hold	966	–	–	﹤0.01%	708
2024 Q3	$8.04K	Hold	966	–	–	﹤0.01%	628
2024 Q2	$6.13K	Hold	966	–	–	﹤0.01%	521
2024 Q1	$5.85K	Hold	966	–	–	﹤0.01%	538
2023 Q4	$5.86K	Buy	+966	New	+$4.3K	﹤0.01%	542

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Fortitude Family Office's AMRX Position: Q2 2026 in Review

Fortitude Family Office increased its Amneal Pharmaceuticals (AMRX) stake by 4.4% in Q2 2026, buying an estimated $466 and bringing the position to 800 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #656.

Fortitude Family Office first reported a position in AMRX in Q4 2023 and has held it in 11 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Fortitude Family Office held 800 shares of Amneal Pharmaceuticals worth $13.8K as of Q2 2026.
Fortitude Family Office bought 34 Amneal Pharmaceuticals shares in Q2 2026, an estimated $466.
Amneal Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #656 holding.
Fortitude Family Office first reported a position in Amneal Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.